1. Medtech Insight
  2. >>Device Area
  3. >>Cardiology

Clinical Data Double-Boost Supports Medtronic's HeartWare Investment

 
• By Reed Miller

Results of the LATERAL trial presented at the recent ISHLT conference show Medtronic's HVAD can be implanted safely through a thoracotomy procedure instead of the standard sternotomy approach, which is far more invasive. At the same meeting, subset data from the ENDURANCE trial confirms that the sickest heart-failure patients treated with HVAD have similar outcomes as less sick patients, and results of the ENDURANCE Supplement show that blood pressure management minimizes the risk of stroke with HVAD.

hvad handshot plam high
Medtronic's HVAD ventricular assist device • Source: Source: Medtronic

Medtronic PLC received two pieces of good news about its HVAD ventricular assist device at the International Society for Heart and Lung Transplantation (ISHLT) Scientific Meeting in San Diego, with encouraging results reported from the LATERAL and ENDURANCE trials.

HVAD, which Medtronic acquired when it bought HeartWare for $1.1bn in August 2016, is approved in Europe as a bridge-to-transplant...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiology

More from Device Area

Siemens Healthineers Mitigates Headwinds With ‘Value-Add Structural Changes’

 
• By Natasha Barrow

Siemens Healthineers anticipates €400m-€500m tariff impact by 2026 but says it will mitigate losses through structural changes and pricing. Despite a revenue decline in diagnostics due to China’s VBP, diagnostics transformation activities, including cutting product, were “successful."

Biostate AI Builds Global RNA-AI Pipeline With $12M Boost, Ventures In China And India

 
• By Shubham Singh

Biostate AI has set up an Indian subsidiary, Bayosthiti, to develop cancer and cardiac diagnostics with local hospitals. This follows a joint venture with China's Kindstar Global and mirrors Biostate’s US collaboration with Mass General Brigham to build AI models for melanoma.

CorTec Begins First Human Trial Of Wireless Brain Implant For Stroke Rehab

 
• By Marion Webb

Germany’s CorTec has implanted its wireless brain-computer interface in a stroke patient, launching a trial to test safety and whether brain stimulation during physical therapy can help restore movement where traditional rehab has failed.